Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer

Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes this simp...

Descripción completa

Detalles Bibliográficos
Autores principales: Priolo, Carmen, Loda, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905328/
https://www.ncbi.nlm.nih.gov/pubmed/27308491
http://dx.doi.org/10.1080/23723556.2014.1001197
_version_ 1782437248622395392
author Priolo, Carmen
Loda, Massimo
author_facet Priolo, Carmen
Loda, Massimo
author_sort Priolo, Carmen
collection PubMed
description Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes this simplistic interpretation obtained from experimental models more challenging. Metabolic reprogramming as a function of distinct molecular aberrations has major diagnostic and therapeutic implications.
format Online
Article
Text
id pubmed-4905328
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49053282016-06-15 Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer Priolo, Carmen Loda, Massimo Mol Cell Oncol Author's View Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes this simplistic interpretation obtained from experimental models more challenging. Metabolic reprogramming as a function of distinct molecular aberrations has major diagnostic and therapeutic implications. Taylor & Francis 2015-01-23 /pmc/articles/PMC4905328/ /pubmed/27308491 http://dx.doi.org/10.1080/23723556.2014.1001197 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Priolo, Carmen
Loda, Massimo
Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
title Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
title_full Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
title_fullStr Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
title_full_unstemmed Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
title_short Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
title_sort untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905328/
https://www.ncbi.nlm.nih.gov/pubmed/27308491
http://dx.doi.org/10.1080/23723556.2014.1001197
work_keys_str_mv AT priolocarmen untargetedmetabolomicsforprofilingoncogenespecificmetabolicsignaturesofprostatecancer
AT lodamassimo untargetedmetabolomicsforprofilingoncogenespecificmetabolicsignaturesofprostatecancer